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Although cohort studies which are based on intention-to-treat (ITT) approach offer a 
simple design with data which are simpler to analyse and results easier to interpret, 
such studies also intrinsically assume that any time-varying treatment effect that exits 
can be adequately estimated by a fixed-effect component. However, such an 
assumption may not reflect real-life drug use. Reflection of real-life clinical practice is a 
major strength of epidemiologic safety studies. The failure to properly reflect reality may 
result in effect under-estimation leading to false and irreproducible conclusions due to 
exposure misclassification. In effect, the use of nested case-control design is a 
concession that ITT in cohort design may not be adequate. But the nested design also 
has its own sources of bias, including confounding by indication. We present an 
overview of the counter-matched version of the nested case-control, case-crossover, 
case-in-time, case series and case-cohort designs as alternatives in prospective post-
authorization safety studies. 
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INTRODUCTION 
 
Pharmacoepidemiological studies are becoming more common in the EU regulatory 
framework for drug safety assessments, thanks largely to Article 1(15) of Directive 
2001/83/EC which defines a post-authorisation safety study (PASS) as either 
“pharmacoepidemiological study or a clinical trial carried out in accordance with the 
terms of marketing authorisation, conducted with the aim of identifying or quantifying a 
safety hazard relating to an authorised medicinal product”. The main reason for their 
popularity may lie in their non-experimental nature- being essentially observational in 
practice and hence, reflecting real-life medical practice. However, observational studies 
are not easy to conduct in the sense of meeting their stated objectives. The main 
difficulty is largely due to the inherent risk of bias associated with these studies. Hence, 
appropriate design, efficient analytical strategy and appropriate interpretation of results 
are vital.  
PASS are based almost entirely on the cohort design which entails recruiting all 
eligible patients with or without exposure to the therapy of interest and subsequently 
following them for a specified period of time.  At the analytic stage, we compare 
exposed patients with the unexposed. However, by design, the exposure status on each 
patient is usually determined at baseline or at a specified time point from recruitment, 
considered as the formal start of follow-up. Thus, an intention-to-treat (ITT) assumption 
is made in the analysis of the resulting data. ITT analysis is one that is based on the 
initial treatment intent and not necessarily on the treatment eventually administered. 
Cohort studies which are based on intention-to-treat approach involve simple designs 
which offer datasets that are simpler to analyse and its results are easier to interpret. Of 
course, the ITT assumption suggests any time-varying treatment effect can be 
adequately estimated by a fixed average. In effect, we assume that exposure occurs 
continuously and the duration of exposure is identical for all exposed patients. However 
intermittent exposure is more common in real-life medical practice than may be 
assumed and the problems associated with simplistic assumptions on exposure 
classification in pharmacoepidemiological studies have been highlighted elsewhere [1-
2].  
In a clinical trial, the aim of the ITT assumption is to estimate the effect of the 
decision to apply the treatment and the analysis considers treatment groups as 
allocated regardless of compliance. Thus, the analysis provides information about the 
potential effects of treatment policy rather than on the potential effects of the specific 
treatment. By contrast, because treatment allocation is informative in an observational 
study, adoption of the ITT assumption will mean estimation of the effect of the decision 
to make the treatment available. Thus ITT assumption on exposure classification may 
be suitable in a clinical trial PASS where random assignment of therapy can ensure its 
validity. Indeed, the assumption is effected in clinical trials to avoid the effects of 
crossover and drop-out which may break the randomization to the treatment groups. 
However, for randomized safety trials there are potential dangers- poor adherence to 
treatment will tend to yield inaccurate estimates of the safety of the treatment under 
study due to exposure misclassification. In observational studies where the absence of 
randomization makes the potential for confounding our main concern, identification of 
the actual exposure of the individuals can help to reduce misclassification.  Indeed, 
reflection of actual drug use is perhaps, the most compelling strength of 
pharmacoepidemiological safety studies. We know that failure to properly reflect reality 
may mean exposure misclassification which for a safety study may result in effect 
under-estimation, false and irreproducible conclusions. In effect, the use of the nested 
case-control design in certain observational cohort studies can be viewed as a form of 
concession that ITT in observational studies may not be adequate. Furthermore, the 
need to ensure comparability between the exposed and unexposed patients in an 
observational cohort design often results in the exclusion of a large number of the study 
population at the analytical stage- making data collection a costly handicap of the 
prospective version of the design. 
Unfortunately, although modelling treatment as time-dependent can be an option to 
ITT in observational studies, the approach has its own assumptions, some of which may 
be difficult to satisfy in a PASS setting where inappropriate application can lead to a 
more profound form of bias- false association. The validity of the time-dependent 
treatment model depends on satisfaction of the relatively strong assumption that the 
reason for change of exposure status is unrelated to the subsequent probability of an 
event. Thus the channelling of a drug may increase the likelihood of detecting a false 
adverse effect as more patients receive the drug when they have a poorer prognosis. In 
any case, time-dependent treatment effects are not that simple to interpret, especially 
when the issue is about the safety or otherwise of a drug and quite rightly, simple but 
clear message remains a general preference. 
We present an overview of the nested case-control, case-crossover, case-in-time, 
case series and case-cohort designs which we propose as alternatives in 
pharmacoepidemiological PASS involving prospectively collected data. In particular, we 
(1) highlight the potential of counter-matching for improving the efficiency of the nested 
case-control design and (2) describe how the case-cohort design can be adopted to 
extend safety assessment activities beyond the unblinding phase of post approval 
clinical trials.  
 
THE ALTERNATIVES 
Counter-matched nested case-control design: 
The nested case-control design offers a simple method for avoiding unreasonable 
assumptions in the evaluation of time-dependent treatment effect [3]. For a given event 
of interest, the design involves identifying suitable controls (i.e. patients free of the 
event) at each time of an event which are then matched to the case (i.e. patient with the 
event) based on a prior specified confounding factors. The process of control selection 
is usually by random sampling and controls can be future cases. The results of the 
nested case-control design are easy to interpret [4-6]. Although the main strength of the 
design rests largely on the appropriateness of the controls that are matched to the 
cases, not much effort is generally made to evaluate its efficiency.  
Matching controls to cases on a confounding variable can improve the precision of 
the comparison of exposure groups although the effect of that variable cannot then be 
estimated. Whilst we do not match on the exposure variable, we still cannot estimate 
exposure effect, if in the matched data, all the cases are of the same exposure status 
and same will be true if all the controls are of the same exposure status or the status is 
the same on each matched pair. In other words, effect estimation is based entirely on 
the off-diagonal data of the resulting stratum-based 2x2 tables in the conditional logistic 
regression. Consequently in theory, the more such matched pairs our sampling can 
generate the more improvement we can expect on efficiency. 
As illustration, suppose for any particular risk set have Ne and Nu as number of 
exposed and unexposed subjects respectively from which we are to draw m controls. 
Then the nested case-control set will contain n=m+1 subjects and suppose the split of 
these n subjects between exposed and unexposed is ne and nu. 
When controls are drawn by simple random sampling of the risk sets, the resulting 
data may be comprised of an uneven split of exposed and unexposed subjects which 
can affect the efficiency of the design. To optimise efficiency, statistical theory suggests 
counter matching cases and controls on exposure status based on information in the full 
cohort [7]. Where this approach is adopted, data collection can be limited to only the 
cases and the sample of patients matched to the cases on a set of baseline 
characteristics that are specified a prior. According to statistical theory, analysis of this 
small cohort is capable of reproducing the results from a full cohort analysis free of time-
varying exposure effect and confounding variables.  
When sampling in this way the contribution of each risk set to the partial log 
likelihood must be adjusted to reflect the fact that the exposure in the sample is different 
from the exposure distribution in the risk set. The modified log partial likelihood 



















Where W are risk weights for each subject which compensate for the sampling.  
These weights take the values: Ne/ne for an exposed subject and Nu/nu for an 
unexposed. The choice of weights depends only on exposure status and not upon 
whether the subject is a case or a control.  
Thus, in the prospective framework, it will not be necessary to collect all data on all 
patients beyond the baseline, which should translate to cost savings. Indeed, the 
counter-matched nested case control design can be particularly attractive in a 
prospective study where (1) the interest is on either a particular event or a prior 
specified collection of events, (2) we do not wish to collect a lot of data and/or (3) the 
cost of a normal registry/cohort will be too high. 
Never the less, the nested case-control design is generally inadequate if the reason 
for the treatment may be associated with the particular outcome of interest, in which 
case the design may present problems such as confounding by indication [8], 
susceptibility bias [9] and/or channelling bias [10]. Since matching controls to cases on 
a confounding variable can improve the precision of the comparison of exposure 
groups, we can reduce the bias due to confounding by incorporating a balancing 
statistic as one of the matching variables. Such a balancing tool can be derived using 
either propensity scores [11-14] or the Heckman selection models [15-18]. 
 
Case-crossover Design: 
In situations where it may be difficult to find adequate comparable controls to the 
cases in a nested case control design, a case-crossover design may be preferable. 
Cross-over is a term used to describe experiments (i.e. clinical trials) in which all 
subjects serve in the treatment and placebo groups at different times of the study. The 
case-crossover design considers the cases themselves as the best representatives of 
the population base that produces them [19]. Thus only cases with dynamic exposure 
status (i.e. periods of exposure and non-exposure) are included in the study, with each 
serving as his/her own control. Indeed, the controls are the same cases but at earlier 
times and as such, the design is based on subject-matched sampling. Exposure 
frequencies from the case window (i.e. current period) and the control window (i.e. 
reference period) are compared through a matched odds ratio.  
 
To illustrate how easy it is to apply, we consider the following as the number of patients 
such that the observed odds of exposure is: ai/bi divided by Nei/Nui.: 
 Exposed Unexposed Total 
Case ai bi ai + bi 
Control Nei Nui Nei + Nui 
Total ai + Nei bi + Nui Ti 














This odds ratio is a measure of association between exposure and risk which can be 
computed for several subgroups and it is generally considered the best statistical 
adjustment for confounding variables with time-constant effects. Indeed, the design is 
particularly good for reducing the effect of unmeasured confounding [20]. 
However, an inherent assumption in the case-crossover design is a constant subject-
specific exposure distribution: exposure should have the same distribution in case and 
control times [21]. Thus, bias may result when the assumption is not valid. Although a 
bidirectional sampling of control windows could eliminate part of the bias from exposure 
time trend [22], the choice of a control window may still be troublesome because of 
problems of induction periods and carry-over effects.  
The case-crossover design is useful for assessing the transient effect of risk factors 
for diseases with acute onset. However it is not appropriate for chronic diseases or 
diseases with carry-over risk effects [23]. The design offers the following advantages: 
 Control selection bias is eliminated as the cases act as their own controls. Thus 
the design can be very useful for studies where choice of appropriate controls is 
a problem or where ethical issues prevent the involvement of control patients. It 
is particularly useful for common vaccine studies. 
 In the prospective framework, we can restrict collection of detailed information to 
the cases with dynamic exposure status. 
 Fewer resources are needed since there is no need to collect information on 
time-constant factors or a separate group of controls. 
 Bias due to confounding by indication will be eliminated or reduced if the reasons 
for prescribing are relatively constant over the period of the study.  
However, the design also has the following disadvantages: 
 Due care is required in the interpretation of the risk ratio estimates. 
 Self matching can decrease precision if the number of concordant pairs is high 
(i.e. the exposure is long lasting and bridges periods). 
 There is always the danger that due to variations in disease severity, the cases 
may form a genuinely distinct group of patients from the population they purport 
to represent. 
 The odds ratios estimates, being based solely on the cases may also represent 
the natural increase in drug use over the time and not just the increase 
associated with the event. This is because by design, a portion of the effect of 
any natural time trend in medication use will be included in the estimates. 
 It is not suitable if exposure effect is not transient 
 
Case-in-time Design: 
This design is an extension of the case-crossover design as it takes into account, 
changes in drug utilization over time, thereby separating the effects of the drug and time 
[24-25]. The effect of time can result from changes in disease severity or the spectrum 
of stages of a disease which can be an important confounding factor. The design 
incorporates both the case-crossover and nested case-control designs. From the case-
crossover design, we select all cases with dynamic exposure status but from the nested 
case-control design, we only select all the matched control subjects with dynamic 
exposure status which we call the “controls”. The resulting patients are then self-
matched based on the current and reference periods as in the case-crossover design to 
constitute the pairs. 
The case-time-control design is based on two main assumptions:  
 That the odds ratio from the case-crossover design is the product of the odds 
ratio due to exposure and the odds ratio due to time trend in exposure 
prevalence 
 That the time trend is the same among the cases and “controls” 
 
For our estimations, we assume conditional independence of exposure within each pair. 
This allows us to use the conditional logistic regression model to estimate the odds 
ratios for period and outcome effects. Conditional analysis automatically eliminates the 
nuisance parameters induced by the subject effects which inherently includes the 
effects of disease severity. With exposure as an independent variable and period as the 
dependant variable we estimate the portion of the risk associated with the period effect 
from the “controls” whilst from the cases, we obtain the estimate associated with both 
period and exposure. Thus, to obtain the odds ratio estimate for drug effect we divide 
the odds ratio estimate from the cases by the odds ratio estimate from the “controls”. 
The case-time-control design offers the following advantages: 
 It permits separation of the effect associated with the drug from that of disease 
severity, even if this severity is not measured 
 Information bias may turn out to be of a less concern than in the case-crossover 
design: indeed if exposure measures are obtained the same way for cases and 
controls, any bias induced by time should cancel out  
 It is particularly suitable for assessing transient effect of treatment where the 
outcome is an acute onset disease. However, it can be used to assess exposure 
effect over a window of up to a year. 
 It is best when the exposure trends can be estimated with great precision and the 
degree to which it provides unbiased results is dependent upon how well these 
trends are estimated 
 In the prospective framework, we can restrict collection of detailed information to 
the cases and matched controls with dynamic exposure status. 
However, the design also has the following disadvantages: 
 Selection bias is possible where exposure change among cases is different from 
exposure change among the “controls” 
 If severity, which is associated with drug use also increases (or decreases) within 
subjects over time, and does so differently for case and control subjects, what is 
believed to be the residual effect associated with the drug could well remain 
confounded to some extent [21, 24-26] 
 It usually produces effect estimates that are systematically lower than those from 
the case-control design [27]  
 The within subjects correlation induced by this design may result in less precise 
effect estimate. But the apparent loss is an artefact since the case-control 
approach produces biased estimates of drug effects, confounded by disease 
severity. The precisions are thus not comparable [28] 
 
Case series Design: 
Like that of the case-crossover, this design is also based on cases only but it is 
particularly suitable for prospective observation where we can restrict collection of 
detailed information to the cases. Furthermore, the design specifically addresses the 
problem of intermittent exposures and acknowledges the role of concomitant factors 
which can influence the hazard rates differentially during periods of exposure and non-
exposure [29]. It does this by assuming piecewise constant hazard functions over fixed 
periods of observation. The null hypothesis is usually that the event rates remain 
constant from day to day and are not affected by the exposure. The periods of 
observation are usually specified a prior, beginning with the exposure period which 
starts from the date of exposure. All the other observation periods are then collectively 
considered as the baseline periods (i.e. without exposure).  For a patient with multiple 
exposures, it is normal to consider each exposure as constituting a separate set of 
exposure and baseline periods, provided the patient can be reasonably considered as 
being at risk in each of the periods. By treating each period as a stratum, hazard ratios 
are then calculated for events that occur within each stratum of the period of exposure 
as compared with the baseline periods. The design can offer simple and objectively 
measurable criteria for the assessment of drug safety [30-32].  
 
Case-cohort Design: 
For situations where the interest is on multiple events, we recommend the use of the 
case-cohort design. The design can facilitate effective assessment of multiple outcomes 
without much of the problem of correlated effects [33-35]. It is most useful for analysing 
time to failure in a large cohort in which failure is rare, such as in the study of serious 
adverse drug effects. The case-cohort design involves randomly selecting a 
representative sample of the patients in the full cohort, irrespective of case status 
(known as the sub-cohort). Relevant baseline information is collected on every member 
of the sub-cohort and also on those patients in the remainder of the full cohort who 
experience the events of interest. Another of its distinctive features is that where as 
each member of the sub-cohort can contribute to the risk set up to the time of being a 
case or censored, a case outside the sub-cohort will only contribute at the exact time of 
becoming a case.  
In the prospective framework, the case-cohort design can be used to address the 
problem of intermittent exposure more easily than in a full cohort. We can afford to 
update the relevant sets of information on members of the corresponding risk set at 
each event point (i.e. the  case and remaining sub-cohort members) which for time-
varying exposure, we can treat as a categorical variable in the same way as in the 
nested case-control design. We see a role for this design for continued assessment of 
serious adverse drug effects over a longer period of time at the end of on-going Phase 
IV trials. The sub-cohort can be easily obtained as a random (possibly stratified) sample 
of the new study population (i.e. the consenting trial population around the time of 
unblinding) to generate useful prospective data. 
To encourage interest in the design as a promising approach to risk estimation, we 
present the essential elements of its formulation.  
 
Computational Formulation: 
In a cohort design, we usually adopt the proportional hazards model to obtain the risk 
estimates.  In doing so, we rely on three main assumptions on the resulting partial 
likelihood- (1) independent failure times and a censoring process that is independent of 
that of failure, (2) with an unspecified underlying hazard, no additional information about 
the risk can be obtained from time intervals with no failure and (3) information 
contributed by a single risk set does not generally increase by virtue of its size [36-37]. 
These assumptions suggest considerable economy may be achieved at little cost in the 
precision of the estimate by comparing “failure” with only a random sample of those at 
risk at the given time. Insight into the loss of precision to be expected due to the 
discarded numbers at risk is given by the standard formula for variance of the difference 
in the means of independent samples.  
The same assumptions facilitate consideration of the case-cohort design as an 
alternative, where the risk set is constituted only by members of a sub cohort. The 
results are a pseudo-likelihood which mimics a form of the partial likelihood for the risk 
estimation and a variance estimation that requires computation of the covariance 
among the score components arising from the sampling design [38]. Although the score 
components are likely to be correlated, the design allows for direct estimation of the risk 
ratio (i.e. ratio of incidence proportions between exposed and unexposed), without the 
rare-disease assumption associated with case-control [39]. Indeed, a jack-knife 
approach which is based on estimates of the influence function (i.e. the influence of 
each individual on the risk and on the overall score) and is computationally more 
efficient and generalizable to other sampling scheme is now available [34-35].  The new 
method is concerned with the contribution of the score function of each individual 
summed over failure times, rather than contributions at each failure time summed over 
individuals. The variance estimate is identical to a robust variance estimator- robust to 
misspecification of the model and measures of influence of individual observations can 
be easily obtained for sensitivity analysis [40-41]. Furthermore, the jack-knife approach 
also provides an adequate correction for the correlation of the risk estimates which may 
result from the assessment of multiple outcomes. The statistical software- SAS (version 
8.2; SAS Institute; Cary, NC) has within its PHREG procedure, the relevant option for 




In pharmacoepidemiological studies, the popular intent-to-treat assumption on 
exposure classification may be unsuitable. Exposure is seldom continuous in real-life 
and intermittent drug intake is common practice. For safety studies, such bias can result 
in effect underestimation and possibly, wrong conclusions and contradictory 
irreproducible estimates. This is a problem we ignore when we design a simple registry 
to assess the safety of a given drug. This is in addition to the problem of selection bias 
which is common in observational studies due to the absence of random assignment of 
treatment. To reduce the effect of selection bias, it is usual practice to select from the 
study population, only exposed and unexposed patients that are comparable on key 
confounding factors. Consequently, we often end up discarding much of the data 
collected in the registry. 
The nested case-control design which is based on a set of matched cases and their 
controls (i.e. matching on certain key factors) from the registry, generally offers a better 
option for safety studies. However, the design is also subject to selection bias capable 
of presenting similar problems. We suggest that by adopting the counter-matched 
version of the design and incorporating an appropriate group balancing instrument, we 
can reduce the problems of exposure misclassification and selection bias considerably 
to produce results robust enough to meet our objectives. 
Of course, the cohort design offers the best option where the problem of intermittent 
drug exposure is not an issue and the case-cohort design can be a viable alternative to 
a full cohort. Indeed, the design can be utilized even where the problem exits. Although 
the case-cohort design is widely recognised as efficient and conceptually simple, it is 
rarely utilised in non-interventional PASS largely due to perceived analytical 
complexities. The design offers an option for continued collection of all relevant data on 
patients in a random subset of a registry that is about to come to its end. Indeed, where 
feasible, this design can complement current efforts aimed at improving the usefulness 
of Phase IV trials on drug safety. It offers a means for an extended follow-up of some of 
the study patients and for assessing multiple potential safety outcomes at improved 
statistical efficiency and without the huge resources which extended trials would entail. 
We see these as sufficient reasons for further assessment of the design and its 
consideration for application in post-market drug safety studies.
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